This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Setoguchi, S. Articles by Winkelmayer, W. C. Search for Related Content PubMed Articles by Setoguchi, S. Articles by Winkelmayer, W. C. Related Collections Related Articles

CLINICAL RESEARCH: ACUTE MYOCARDIAL INFARCTION

Improvements in Long-Term Mortality After Myocardial Infarction and Increased Use of Cardiovascular Drugs After Discharge

A 10-Year Trend Analysis

Soko Setoguchi, MD, DrPH^_*,_*, Robert J. Glynn, PhD, ScD^_*, Jerry Avorn, MD^_*, Murray A. Mittleman, MD, DrPH, Raisa Levin, MS^_* and Wolfgang C. Winkelmayer, MD, ScD^_*,

^_* Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
Renal Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.

Manuscript received July 23, 2007; revised manuscript received October 12, 2007, accepted October 17, 2007.

^_* Reprint requests and correspondence: Dr. Soko Setoguchi, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, 1620 Tremont Street, Suite 3030, Boston, Massachusetts 02120. (Email: soko{at}post.harvard.edu).

Objectives: We sought to assess the relationship between increasing use of cardiovascular medications and trends in long-term prognosis after myocardial infarction (MI) in the elderly.

Background: During the past decade, statins, beta-blockers (BBs), angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin-II receptor blockers (ARBs) have been increasingly used after MI. However, little is known about the relationship between increasing use of these medications and improvements in prognosis after MI.

Methods: Using data from pharmacy assistance programs and Medicare in 2 states (1995 to 2004), we identified patients with MI who survived 30 days after discharge. We assessed age, gender, race, comorbidities, and coronary interventions during the MI hospitalization and recorded filled prescriptions for statins, BBs, ACEIs/ARBs, or antiplatelet agents within 30 days after discharge. All patients were tracked until they died or until the end of the eligibility/study period. We built multivariate Cox proportional hazards regression models to assess trends in long-term mortality and the contribution to increasing medication use after MI.

Results: Of 21,484 patients identified, 12,142 died during 74,982 person-years of follow-up. After adjusting for demographics and comorbidities, we found that mortality after MI decreased significantly from 1995 to 2004 (hazard ratio for annual trend 0.97; 95% confidence interval 0.97 to 0.98), a 3% reduction in mortality each year. Adjusting for the use of statins, BBs, ACEIs/ARBs, and antiplatelet drugs after discharge completely eliminated the association between time trend and mortality (hazard ratio 1.00; 95% confidence interval 0.99 to 1.01).

Conclusions: The observed improvement in long-term mortality in elderly patients with MI may be mainly due to increased use of cardiovascular medications after discharge.

Abbreviations and Acronyms   ACEI = angiotensin-converting enzyme inhibitor   ARB = angiotensin-II receptor blocker   BB = beta-blocker   MI = myocardial infarction   NSTEMI = non–ST-segment elevation myocardial infarction   PCI = percutaneous coronary intervention

Related Articles

Reducing Post-Myocardial Infarction Mortality in the Elderly: The Power and Promise of Secondary Prevention

William E. Boden and David J. Maron
J. Am. Coll. Cardiol. 2008 51: 1255-1257. [Full Text] [PDF]

This article has been cited by other articles:

				F. W.A. Verheugt Reperfusion Therapy for ST-Segment Elevation Myocardial Infarction: Trials, Registries, and Guidelines Circulation, June 23, 2009; 119(24): 3047 - 3049. [Full Text] [PDF]

				P. M. Ho, C. L. Bryson, and J. S. Rumsfeld Medication Adherence: Its Importance in Cardiovascular Outcomes Circulation, June 16, 2009; 119(23): 3028 - 3035. [Abstract] [Full Text] [PDF]

				A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al. Highlights of the Year in JACC 2008. J. Am. Coll. Cardiol., January 27, 2009; 53(4): 373 - 398. [Full Text] [PDF]

				T. Briffa, S Hickling, M Knuiman, M Hobbs, J Hung, F M Sanfilippo, K Jamrozik, and P L Thompson Long term survival after evidence based treatment of acute myocardial infarction and revascularisation: follow-up of population based Perth MONICA cohort, 1984-2005 BMJ, January 26, 2009; 338(jan26_2): b36 - b36. [Abstract] [Full Text] [PDF]

				E. R. Jenny-Avital, F. L. Luan, K. Nguyen, T. A. Tobey, A. Parashar, R. P. Byington, H. C. Gerstein, W. T. Friedewald, A. Patel, S. MacMahon, et al. Intensive Glucose Control in Type 2 Diabetes N. Engl. J. Med., October 2, 2008; 359(14): 1519 - 1521. [Full Text] [PDF]

				W. E. Boden and D. J. Maron Reducing Post-Myocardial Infarction Mortality in the Elderly: The Power and Promise of Secondary Prevention J. Am. Coll. Cardiol., April 1, 2008; 51(13): 1255 - 1257. [Full Text] [PDF]